Physician profile
Khalid Rayaz
NPI 1023107935
$818.06
in general payments reported to CMS, 2019-2025
18 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2021: $14.65 · 2022: $51.71 · 2023: $71.91 · 2024: $250 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $118.27 | 2024 | Brixadi |
| Orexo US, INC. | $111.76 | 2019 | |
| Biogen, INC. | $90.52 | 2024-2025 | Vumerity, Skyclarys |
| Abbvie INC. | $81.11 | 2023-2025 | |
| Mdd US Operations, LLC | $80.52 | 2019 | |
| Ucb, INC. | $38.70 | 2023-2024 | Briviact |
| Neurelis, INC. | $38.62 | 2025 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $37.53 | 2025 | |
| Indivior INC. | $34.75 | 2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.81 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $26.08 | 2025 | |
| Banner Life Sciences, LLC | $23.04 | 2023 | |
| Lundbeck LLC | $22.44 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $20.24 | 2022 | |
| Neurocrine Biosciences, INC. | $16.60 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.55 | 2023 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $14.87 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Rayaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.